New PET tracer aims to reveal which cancers will respond to immunotherapy
NCT ID NCT07140315
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new radioactive imaging agent, [18F]DK222, in 6 people with non-small cell lung cancer or urothelial cancer. The agent is designed to attach to PD-L1, a protein that helps cancer hide from the immune system. Researchers want to see if the agent is safe, how it moves through the body, and how much radiation it gives off. This is not a treatment—it is a way to potentially improve cancer imaging.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[18F]DK222 radiotracer
What this could lead to
If successful, this could lead to a better way to see which cancers might respond to immunotherapy, helping doctors choose the right treatment.
What could go wrong
This is a very early, small study with only 6 people. The imaging agent may not work as hoped, or safety issues could arise. It is not a treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins Hospital
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact